Package Insert SEARCH
Medical calc categories
New Drug Approvals
Google Site SEARCH
Arterial Blood Gas (ABG) Analysis
Anion Gap / Serum Osmolality
Common Laboratory (LAB) Values
Conventional- S.I. Units
Cerebrospinal fluid analysis
Adult Treatment Panel III
Opioids - Equianalgesic Dosages
Clinical concerns - Geriatric Pts
Renal Dosing Protocols
Important equations (four)
Continuing Education Links
Guest book (old)
Consumer Links (old section)
About this site
CHADS2 Score: Stroke Risk Assessment in Atrial Fibrillation
The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE
CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Condition / Points
Congestive heart failure (Points: 1 )
Hypertension: blood pressure consistently above 140/90 mmHg (or treated hypertension on medication) (Points: 1 )
75 years (Points: 1 )
Diabetes Mellitus (Points: 1 )
Prior Stroke or TIA (Points: 2 )
score: clinical prediction rule for assessing the risk of stroke in patients with non-rheumatic atrial fibrillation. The result can be used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy. A high CHADS
score corresponds to a greater risk of stroke, while a low CHADS
score corresponds to a lower risk of stroke. The CHADS
score was validated by a study of nonrheumatic atrial fibrillation patients aged 65 to 95 who were not prescribed the anticoagulant warfarin.
[1 ] Gage BF, van Walraven C, Pearce L, et al. (2004). "Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin". Circulation 110 (16): 2287–92.
[2 ] Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001). "Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation". JAMA 285 (22): 2864–70.
[3 ] Go AS, Hylek EM, Chang Y, et al. Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation: How Well Do Randomized Trials Translate Into Clinical Practice? JAMA. 2003;290(20):2685-2692
All calculations must be confirmed before use. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgement. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Read the disclaimer
Medical Calculators - A thru Z
Lab Values - A thru Z
This site complies with the
HONcode standard for trustworthy health